ANI looks to boost pipeline with WellSpring Pharma acquisition
ANI Pharmaceuticals on Tuesday announced its acquisition of WellSpring Pharma Services, a Canadian contract development and manufacturing organization, or CDMO. The company said the acquisition is expected to boost its efforts to increase its generics pipeline.
“In the second quarter of 2018, ANI continued to successfully execute on its strategy to grow the brand and generic business platforms, and to advance our key pipeline assets. In addition, today, we announced that we acquired WellSpring, a contract development and manufacturing business located near Toronto, Canada in order to expand our third business platform, contract manufacturing, and to increase our capacity to re-commercialize our pipeline of acquired ANDAs that require a tech transfer,” Arthur Przybyl, ANI president and CEO, said.
WellSpring has capabilities in solid oral, semi-solids and liquids. The company has about 100 employees and a 100,000-sq.-ft. site that ANI has acquired as part of the transaction. WellSpring currently generates $15 to $20 million dollars in annual revenues.
With a focus on brand and generic drug products, WellSpring currently manufactures 17 commercial products for 11 different customers, and is assisting customers on 13 additional products that are in development or awaiting FDA approval, according to ANI.
The site manufactures drug products for the United States and Canadian prescription drug markets, and has substantial capacity, ANI said.
FDA approves new indication, vial presentation for Teva’s Granix
Teva has received the green light from the Food and Drug Administration for a new indication and vial presentation of its Neupogen biosimilar, Granix (tbo-filgrastim), the company announced Tuesday. It is now indicated in pediatric patients one month old and older.
The product is indicated to reduce the duration of severe neutropenia in adult and pediatric patients one month old and older with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Teva said the product will now be available in 300 mcg/1 ml and 480 mcg/1.6 ml single-dose vials, with its prefilled syringe presentation still available.
“The new pediatric indication and vial presentation of Granix expand the range of treatment options that can be of benefit to both patients and healthcare providers,” said Brendan O’Grady, Teva’s executive vice president and head of North America commercial.
Albertsons stocking flu vaccine at its pharmacies
Albertsons is ready for flu season. The Boise, Idaho-based company announced Monday that its pharmacies are currently stocking the flu vaccine for the 2018-2019 flu season.
The Centers for Disease Control and Prevention recommend flu shots for everyone 6 months old and older, with very few exceptions. The company said its pharmacists are able to counsel patients on what vaccine is suitable for their specific health conditions, then administer the vaccine.
Albertsons said that all of the vaccinations it offers as permitted by state law,can be given on a walk-in basis at more than 1,700 of its locations at such banners as Albertsons, Safeway, Vons, Jewel-Osco, ACME and more.
Where permitted, the company said patients who receive an immunization will receive a coupon for a 10% discount on a grocery purchase.